New York city, USA, May 5th, 2026, FinanceWire
PTC Therapeutics entered 2026 focused on a regulatory milestone that could help it treat Huntington’s Disease.
At the J.P. Morgan Healthcare Conference in January, the company announced that it had completed an End-of-Phase 2 FDA meeting for votoplam, its Huntington’s disease program developed in collaboration with Novartis. Regulators had expressed openness to an Accelerated Approval pathway and aligned on a global Phase 3 trial design planned to begin in the first half of 2026.
Armistice Capital holds a position in PTC Therapeutics, alongside other institutional investors tracking the company’s commercial trajectory and the clinical events that votoplam’s Phase 3 initiation could set in motion.
Huntington’s Disease and the Unmet Medical Need
No disease-modifying treatment for Huntington’s disease has been approved in the United States.
The condition, caused by an inherited mutation in the huntingtin gene, produces progressive neurological decline affecting movement, cognition, and behavior, typically beginning in midlife. Approximately 30,000 people in the United States have Huntington’s disease, with another 200,000 estimated to be at risk of inheriting it. Clinicians today are limited to symptomatic management.
Accelerated Approval (a regulatory pathway available when a serious condition with significant unmet need can be evaluated using a surrogate endpoint) is the mechanism PTC and Novartis are now targeting for votoplam.
The surrogate in question is mutant huntingtin protein reduction in the blood. A full approval, if the program advances, would still require a confirmatory trial demonstrating clinical benefit. But the FDA’s signal in 2025 that it found the scientific rationale credible was a substantive step forward for the program.
Phase 2 Data and the Phase 3 Design
The data supporting the Accelerated Approval discussion came from the Phase 2 PIVOT-HD study, results of which PTC reported in May 2025.
Votoplam met its primary endpoint of huntingtin protein reduction with statistical significance (p<0.0001). At the 10mg dose, 12-month reductions of 39% were recorded in Stage 2 patients and 36% in Stage 3; at the 5mg dose, both groups showed 23% reductions. For Stage 2 patients, the data also showed dose-dependent trends of benefit on the Composite Unified Huntington’s Disease Rating Scale and the Total Motor Score subscale. No treatment-related serious adverse events were reported across any dose level or disease stage.
The licensing arrangement with Novartis, closed in 2024, places global Phase 3 sponsorship under Novartis. PTC received $1.0 billion upfront and is eligible for up to $1.9 billion in development, regulatory, and sales milestones.
Under the agreement, PTC would receive a 40% profit share on U.S. sales and tiered royalties on international revenue. The Phase 3 design aligned with the FDA in Q4 2025 has not been detailed publicly in full; the planned initiation window is the first half of 2026.
Commercial Position and 2026 Guidance
PTC’s commercial operations provide the revenue base against which the votoplam timeline plays out.
Total unaudited product and royalty revenue for 2025 came in at approximately $823.4 million, above the guidance range the company had set.
The standout contributor to growth was Sephience (sepiapterin), approved for phenylketonuria in 2025, which generated approximately $112.1 million in net revenue since launch and approximately $92.5 million in Q4 2025 alone.
In December 2025, the company sold its remaining Evrysdi royalty rights to Royalty Pharma for $240 million upfront, plus contingent milestone payments. The transaction reduced a line of recurring income but left PTC with approximately $1.94 billion in cash, cash equivalents, and marketable securities at year-end.
Institutional Investor Context
Armistice Capital’s position in PTC Therapeutics is consistent with the company’s profile as a commercial-stage rare disease firm. PTC has an approved product generating near-term revenue growth and an out-licensed clinical program in a disease area that has produced no approved disease-modifying treatments.
The FDA’s expressed openness to Accelerated Approval does not guarantee it. The regulatory track record in Huntington’s disease is limited enough that any positive Phase 3 data would carry real weight, but the history of the disease also includes programs that showed early biological signals without translating them to clinical benefit. Phase 3 enrollment pace, interim data milestones, and the confirmatory trial design will all be points of focus for investors tracking the program through 2026 and beyond.
About Armistice Capital
Armistice Capital is a global investment management firm and hedge fund based in New York, USA. It was founded in 2012 and focuses on long/short, value-oriented and event-driven investment strategies across multiple sectors, especially in health care and consumer equities. Armistice Capital holds a position in PTC Therapeutics, alongside other institutional investors tracking the company’s commercial trajectory.